Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CCL2



This biomarker is also known as:
  • monocyte chemoattractant protein-1,
  • MCP-1,
  • monocyte secretory protein JE,
  • Monocyte chemoattractant protein 1,
  • MCAF,
  • small-inducible cytokine A2,
  • C-C motif chemokine 2,
  • MGC9434,
  • SMC-CF,
  • Monocyte chemotactic and activating factor,
  • chemokine (C-C motif) ligand 2,
  • Monocyte secretory protein JE,
  • small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
  • Small-inducible cytokine A2,
  • small inducible cytokine subfamily A (Cys-Cys), member 2,
  • MCP1,
  • monocyte chemoattractant protein 1,
  • monocyte chemotactic and activating factor,
  • Monocyte chemotactic protein 1,
  • monocyte chemotactic protein 1,
  • SCYA2,
  • GDCF-2,
  • HSMCR30,
  • HC11,

View in BioMuta


CCL2, also known as MCP-1, is a member of the chemokine superfamily. Chemokines are a family of small cytokines. The four chemokine subfamilies are based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2 is a member of the CC subfamily, characterized by two adjacent cysteine residues. CCL2 is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.